Sonodynamic Therapy Based on Combined Use of Low Dose Administration of Epirubicin-Incorporating Drug Delivery System and Focused Ultrasound

Masanori Maeda, Yoshihiro Muragaki, Jun Okamoto, Shin Yoshizawa, Nobutaka Abe, Hidekazu Nakamoto, Hiroshi Ishii, Kenichi Kawabata, Shinichiro Umemura, Nobuhiro Nishiyama, Kazunori Kataoka, Hiroshi Iseki

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Sonodynamic therapy (SDT) is currently considered as one of the promising minimally invasive treatment options for solid cancers. SDT is based on the combined use of a sonosensitizer drug and high-intensity focused ultrasound (HIFU) to produce cytotoxic reactive oxygen species (ROS) in and around neoplastic cells. Anthracycline drugs, including epirubicin (EPI), have been well known as effective sonosensitizers after interaction with focused ultrasound. Recently a new anticancer drug delivery system (DDS), NC-6300, has been developed that comprises EPI through an acid–labile hydrazone bond. In previous in vivo studies, NC-6300 showed basic drug safety and an excellent concentration property of EPI, and recently has been tested in clinical trials. For realizing minimally invasive cancer treatment, the present study demonstrated the effectiveness and feasibility of DDS-based SDT, which combined a small dose of NC-6300 and low energy of HIFU in mouse models of colon cancer and pancreatic cancer.

Original languageEnglish
Pages (from-to)2295-2301
Number of pages7
JournalUltrasound in Medicine and Biology
Volume43
Issue number10
DOIs
Publication statusPublished - 2017 Oct 1
Externally publishedYes

Fingerprint

Epirubicin
Drug Delivery Systems
therapy
delivery
drugs
dosage
cancer
Pharmaceutical Preparations
Therapeutics
Hydrazones
hydrazones
Anthracyclines
Pancreatic Neoplasms
Colonic Neoplasms
mice
Reactive Oxygen Species
Neoplasms
safety
Clinical Trials
Safety

Keywords

  • Colon cancer
  • Drug delivery system (DDS)
  • Epirubicin
  • High intensity focused ultrasound (HIFU)
  • In vivo
  • Micellar
  • Pancreatic cancer
  • Sonodynamic therapy (SDT)

ASJC Scopus subject areas

  • Radiological and Ultrasound Technology
  • Biophysics
  • Acoustics and Ultrasonics

Cite this

Sonodynamic Therapy Based on Combined Use of Low Dose Administration of Epirubicin-Incorporating Drug Delivery System and Focused Ultrasound. / Maeda, Masanori; Muragaki, Yoshihiro; Okamoto, Jun; Yoshizawa, Shin; Abe, Nobutaka; Nakamoto, Hidekazu; Ishii, Hiroshi; Kawabata, Kenichi; Umemura, Shinichiro; Nishiyama, Nobuhiro; Kataoka, Kazunori; Iseki, Hiroshi.

In: Ultrasound in Medicine and Biology, Vol. 43, No. 10, 01.10.2017, p. 2295-2301.

Research output: Contribution to journalArticle

Maeda, M, Muragaki, Y, Okamoto, J, Yoshizawa, S, Abe, N, Nakamoto, H, Ishii, H, Kawabata, K, Umemura, S, Nishiyama, N, Kataoka, K & Iseki, H 2017, 'Sonodynamic Therapy Based on Combined Use of Low Dose Administration of Epirubicin-Incorporating Drug Delivery System and Focused Ultrasound', Ultrasound in Medicine and Biology, vol. 43, no. 10, pp. 2295-2301. https://doi.org/10.1016/j.ultrasmedbio.2017.06.003
Maeda, Masanori ; Muragaki, Yoshihiro ; Okamoto, Jun ; Yoshizawa, Shin ; Abe, Nobutaka ; Nakamoto, Hidekazu ; Ishii, Hiroshi ; Kawabata, Kenichi ; Umemura, Shinichiro ; Nishiyama, Nobuhiro ; Kataoka, Kazunori ; Iseki, Hiroshi. / Sonodynamic Therapy Based on Combined Use of Low Dose Administration of Epirubicin-Incorporating Drug Delivery System and Focused Ultrasound. In: Ultrasound in Medicine and Biology. 2017 ; Vol. 43, No. 10. pp. 2295-2301.
@article{fe641876be4743e980410ee81071748d,
title = "Sonodynamic Therapy Based on Combined Use of Low Dose Administration of Epirubicin-Incorporating Drug Delivery System and Focused Ultrasound",
abstract = "Sonodynamic therapy (SDT) is currently considered as one of the promising minimally invasive treatment options for solid cancers. SDT is based on the combined use of a sonosensitizer drug and high-intensity focused ultrasound (HIFU) to produce cytotoxic reactive oxygen species (ROS) in and around neoplastic cells. Anthracycline drugs, including epirubicin (EPI), have been well known as effective sonosensitizers after interaction with focused ultrasound. Recently a new anticancer drug delivery system (DDS), NC-6300, has been developed that comprises EPI through an acid–labile hydrazone bond. In previous in vivo studies, NC-6300 showed basic drug safety and an excellent concentration property of EPI, and recently has been tested in clinical trials. For realizing minimally invasive cancer treatment, the present study demonstrated the effectiveness and feasibility of DDS-based SDT, which combined a small dose of NC-6300 and low energy of HIFU in mouse models of colon cancer and pancreatic cancer.",
keywords = "Colon cancer, Drug delivery system (DDS), Epirubicin, High intensity focused ultrasound (HIFU), In vivo, Micellar, Pancreatic cancer, Sonodynamic therapy (SDT)",
author = "Masanori Maeda and Yoshihiro Muragaki and Jun Okamoto and Shin Yoshizawa and Nobutaka Abe and Hidekazu Nakamoto and Hiroshi Ishii and Kenichi Kawabata and Shinichiro Umemura and Nobuhiro Nishiyama and Kazunori Kataoka and Hiroshi Iseki",
year = "2017",
month = "10",
day = "1",
doi = "10.1016/j.ultrasmedbio.2017.06.003",
language = "English",
volume = "43",
pages = "2295--2301",
journal = "Ultrasound in Medicine and Biology",
issn = "0301-5629",
publisher = "Elsevier USA",
number = "10",

}

TY - JOUR

T1 - Sonodynamic Therapy Based on Combined Use of Low Dose Administration of Epirubicin-Incorporating Drug Delivery System and Focused Ultrasound

AU - Maeda, Masanori

AU - Muragaki, Yoshihiro

AU - Okamoto, Jun

AU - Yoshizawa, Shin

AU - Abe, Nobutaka

AU - Nakamoto, Hidekazu

AU - Ishii, Hiroshi

AU - Kawabata, Kenichi

AU - Umemura, Shinichiro

AU - Nishiyama, Nobuhiro

AU - Kataoka, Kazunori

AU - Iseki, Hiroshi

PY - 2017/10/1

Y1 - 2017/10/1

N2 - Sonodynamic therapy (SDT) is currently considered as one of the promising minimally invasive treatment options for solid cancers. SDT is based on the combined use of a sonosensitizer drug and high-intensity focused ultrasound (HIFU) to produce cytotoxic reactive oxygen species (ROS) in and around neoplastic cells. Anthracycline drugs, including epirubicin (EPI), have been well known as effective sonosensitizers after interaction with focused ultrasound. Recently a new anticancer drug delivery system (DDS), NC-6300, has been developed that comprises EPI through an acid–labile hydrazone bond. In previous in vivo studies, NC-6300 showed basic drug safety and an excellent concentration property of EPI, and recently has been tested in clinical trials. For realizing minimally invasive cancer treatment, the present study demonstrated the effectiveness and feasibility of DDS-based SDT, which combined a small dose of NC-6300 and low energy of HIFU in mouse models of colon cancer and pancreatic cancer.

AB - Sonodynamic therapy (SDT) is currently considered as one of the promising minimally invasive treatment options for solid cancers. SDT is based on the combined use of a sonosensitizer drug and high-intensity focused ultrasound (HIFU) to produce cytotoxic reactive oxygen species (ROS) in and around neoplastic cells. Anthracycline drugs, including epirubicin (EPI), have been well known as effective sonosensitizers after interaction with focused ultrasound. Recently a new anticancer drug delivery system (DDS), NC-6300, has been developed that comprises EPI through an acid–labile hydrazone bond. In previous in vivo studies, NC-6300 showed basic drug safety and an excellent concentration property of EPI, and recently has been tested in clinical trials. For realizing minimally invasive cancer treatment, the present study demonstrated the effectiveness and feasibility of DDS-based SDT, which combined a small dose of NC-6300 and low energy of HIFU in mouse models of colon cancer and pancreatic cancer.

KW - Colon cancer

KW - Drug delivery system (DDS)

KW - Epirubicin

KW - High intensity focused ultrasound (HIFU)

KW - In vivo

KW - Micellar

KW - Pancreatic cancer

KW - Sonodynamic therapy (SDT)

UR - http://www.scopus.com/inward/record.url?scp=85021873867&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021873867&partnerID=8YFLogxK

U2 - 10.1016/j.ultrasmedbio.2017.06.003

DO - 10.1016/j.ultrasmedbio.2017.06.003

M3 - Article

C2 - 28705555

AN - SCOPUS:85021873867

VL - 43

SP - 2295

EP - 2301

JO - Ultrasound in Medicine and Biology

JF - Ultrasound in Medicine and Biology

SN - 0301-5629

IS - 10

ER -